Riquelme, Paloma http://orcid.org/0000-0001-8962-3156
Haarer, Jan
Kammler, Anja
Walter, Lisa http://orcid.org/0000-0003-3421-2362
Tomiuk, Stefan
Ahrens, Norbert http://orcid.org/0000-0002-4680-2688
Wege, Anja K. http://orcid.org/0000-0002-8838-0532
Goecze, Ivan
Zecher, Daniel
Banas, Bernhard http://orcid.org/0000-0003-2076-2195
Spang, Rainer
Fändrich, Fred
Lutz, Manfred B.
Sawitzki, Birgit
Schlitt, Hans J. http://orcid.org/0000-0002-3874-0296
Ochando, Jordi http://orcid.org/0000-0001-7037-1681
Geissler, Edward K.
Hutchinson, James A. http://orcid.org/0000-0002-1199-4210
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (HU 1838/1-1, HU 1838/2-1)
Article History
Received: 28 March 2017
Accepted: 8 June 2018
First Online: 20 July 2018
Competing interests
: J.A.H. and E.K.G. are the named inventors on European Patent Office (EPO) filing 16159985.6-1402 dated 11.03.2016, ‘Immunoregulatory cells and methods for their production’. J.A.H., P.R. and E.K.G. are the named inventors on EPO filing 17206021.2-1111, ‘New drug screening assay using regulatory macrophages’, dated 07.12.2017. The remaining authors declare no competing interests. Trizell GmbH holds commercial rights to clinical application of Mreg_UKR as a therapeutic cell-based product.